title: Poor treatment compliance in children with down syndrome and acute lymphoblastic leukemia.
authors.forename: Catherine
authors.initials: C
authors.lastname: Bohnstedt
authors.forename: Mervi
authors.initials: M
authors.lastname: Taskinen
authors.forename: Bernward
authors.initials: B
authors.lastname: Zeller
authors.forename: Helga
authors.initials: H
authors.lastname: Björgvinsdóttir
authors.forename: Solveig
authors.initials: S
authors.lastname: Hafsteinsdottir
authors.forename: Kjeld
authors.initials: K
authors.lastname: Schmiegelow
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004314:Down Syndrome / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy; D010349:Patient Compliance / Q000706:statistics & numerical data*; D010819:Physician's Role; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D015122:Mercaptopurine; D008727:Methotrexate